Omeros Corp OMER

$18.79 +0.36 (1.95%)

Valuation

Market cap
1,334,111,000
Revenue TTM
$0
Net income TTM
$-3,350,000
PE ratio
6.92
Forward PE
—
Profit margin
0.00%
Debt to equity
-1.89

Trading

Volume
931,300
Avg volume
1,758,634
Day's range
$18.30 – $19.08
Shares out
72,388,000
Stochastic %K
35%
Beta
2.57
Analysts
Strong Sell
Price target
$36.67

Price

Company profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COV...

Show more

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
206 676 5000
Website
https://www.omeros.com
Address
The Omeros Building, 201 Elliott Avenue West, Seattle, United States

Latest news

Stocktwits

LeaLeb Oct 16, 2:33 AM
$OMER Going to sleep expecting a small dump tomorrow, anything better than that would make me a great weekend.
3 replies
MayorofMNKD Oct 15, 10:24 PM
$OMER ….looks like a leak says we got approval recommendation
3 replies
MrLucky123 Oct 15, 9:51 PM
$OMER lots of volume last half hour right into bell.
0 replies
hmb Oct 15, 8:28 PM
$OMER did the Trump admin just create a. Infectious disease research division? Does yart not cure infectious disease? And may have many more uses in this area? Did I imagine this?
1 replies
betonthenews Oct 15, 8:02 PM
$OMER Google AI: Potential Scenarios for Tomorrow 1. Negative Stance Confirmed (The Expected Path): OMER stock could experience a immediate knee-jerk dip of 5% to 15% due to retail investor disappointment and the definitive closure of the European market runway. 2. Surprise Positive Reversal (The Upside Path): Because a reversal is highly unexpected, if the CHMP flips to a positive stance, OMER shares would likely skyrocket dramatically, as analysts would immediately have to factor a multi-million dollar European market back into their fair-value estimates. Given that Omeros historically exhibits highly volatile price movements, investors should brace for sharp intraday swings regardless of the formal announcement.
1 replies
StockMktGuru Oct 15, 7:39 PM
$OMER Someone always knows?
0 replies
Phase3 Oct 15, 7:37 PM
$OMER ??????
0 replies
MikeLogan Oct 15, 7:37 PM
$OMER C'mon wizard Greg, show us some magic! 🧙🪄
1 replies